'Uncategorized' Category
By Simmons Hanly Conroy | October 8, 2014
FDA Advises Drugmakers to Conduct Further Studies on Testosterone Heart Risk
An advisory panel to the U.S. Food and Drug Administration (FDA) recently voted 20-1 that further assessment of the health risks of testosterone therapy is needed among drugmakers. Among the panel, 16… Read More
By Simmons Hanly Conroy | October 6, 2014
Risperdal, Weight Gain and Gynecomastia: The Connection
Risperdal is currently used to treat severe psychiatric disorders despite escalating reports of unhealthy weight gain and gynecomastia. Due to the drug’s success and its lack of proper warning, though, doctors continue to… Read More
By Simmons Hanly Conroy | September 2, 2014
5 Gynecomastia Facts You May Not Know
Gynecomastia is a condition that has been linked to the use of Risperdal among adolescent boys. It involves the enlargement of male breasts as well as the secretion of milk. Male breasts… Read More
By Simmons Hanly Conroy | August 26, 2014
How Many Men Really Need Testosterone Replacement Therapy?
More men are turning to prescription medications such as testosterone replacement therapy to combat “low T syndrome.” In the United States, testosterone prescriptions among men have tripled since 2001. What some people… Read More
By Simmons Hanly Conroy | August 22, 2014
Health Canada Flags Testosterone Replacement Therapy for Serious Side Effects
Health Canada has issued a safety warning in its July safety review that testosterone, or low-T, treatments are responsible for increased health risks. The Canadian government organization reviewed various case reports and… Read More
By Simmons Hanly Conroy | July 16, 2014
American Medical Systems Enrolls First Patient in its Largest TVM Study to Date
American Medical Systems (AMS), a subsidiary of Endo International, enrolled the first patient in its mandatory post market surveillance study for the Elevate™ Anterior and Apical Prolapse Repair System. The study is… Read More
By Simmons Hanly Conroy | July 14, 2014
New FDA Warning Against Use of Numbing Medications in Infants
Parents with teething infants should not use “gum-numbing” anesthetics known as viscous lidocaine, the U.S. Food and Drug Administration (FDA) recently reported. When used among infants and young children, such medications can… Read More
By Simmons Hanly Conroy | June 27, 2014
Pharmaceutical News Wrap Up: June 2014
The Firm pharmaceutical lawyers are dedicated to providing you with the latest pharmaceutical news. Below is a short list of some of the most recent headlines concerning FDA recalls, approvals and warning… Read More
By Simmons Hanly Conroy | June 23, 2014
New Risk of Blood Clots Associated with Testosterone Treatments
The US Food and Drug Administration (FDA), announced last week that there has been another risk associated with testosterone treatments. The FDA is now requiring manufacturers of testosterone or low T products must… Read More
By Simmons Hanly Conroy | June 11, 2014
Testosterone Therapy Lawsuits Consolidated Before One Judge
The U.S. Judicial Panel on Multidistrict Litigation has ordered the consolidation of all federal testosterone therapy lawsuits before the Hon. Matthew F. Kennelly in the Northern District of Illinois, U.S. District Court.… Read More